<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39321244</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0019-557X</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Indian journal of public health</Title><ISOAbbreviation>Indian J Public Health</ISOAbbreviation></Journal><ArticleTitle>Navigating the Therapeutic Roller Coaster of COVID-19: Lessons for the Future.</ArticleTitle><Pagination><StartPage>462</StartPage><EndPage>463</EndPage><MedlinePgn>462-463</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/ijph.ijph_1110_22</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sarangi</LastName><ForeName>Sudhir Chandra</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Additional Professor, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Deeksha</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>PhD Scholar, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Public Health</MedlineTA><NlmUniqueID>0400673</NlmUniqueID><ISSNLinking>0019-557X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>22</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>13</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39321244</ArticleId><ArticleId IdType="doi">10.4103/ijph.ijph_1110_22</ArticleId><ArticleId IdType="pii">01586002-202407000-00026</ArticleId></ArticleIdList><ReferenceList><Title>R EFERENCES</Title><Reference><Citation>Number of clinical trial registrations by location, disease, phase of development, age and sex of trial participants (1999-2022). World Health Organization 2023 Available from: https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/number-of-trial-registrations-by-year-location-disease-and-phase-of-development [Last accessed on 2023 Oct 26].</Citation></Reference><Reference><Citation>Coronavirus (COVID-19) |Drugs. U. S. Food &amp;Drug Administration 2023 Available from: https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs [Last accessed on 2023 Oct 26].</Citation></Reference><Reference><Citation>Di Stefano L, Ogburn EL, Ram M, Scharfstein DO, Li T, Khanal P, et al. Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19:An individual participant data meta-analysis. PLoS One 2022;17:e0273526.</Citation></Reference><Reference><Citation>Bartoli A, Gabrielli F, Alicandro T, Nascimbeni F, Andreone P. COVID-19 treatment options:A difficult journey between failed attempts and experimental drugs. Intern Emerg Med 2021;16:281–308.</Citation></Reference><Reference><Citation>Popp M, Reis S, Schießer S, Ilona Hausinger R, Stegemann M, Metzendorf MI, et al. Ivermectin for preventing and treating COVID-19. Emergencias 2023;35:381–3.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>